Original ArticleNanoemulsion strategy of Pioglitazone (cas 111025-46-8) for the treatment of skin inflammatory diseases

Add time:08/28/2019    Source:sciencedirect.com

Pioglitazone (cas 111025-46-8) (PGZ) is a peroxisome proliferator-activated receptor agonist. Its role in the inflammatory response modulation paves the way for additional therapeutic applications. The purpose of this study was to develop a pioglitazone nanoemulsion (PGZ-NE) in order to investigate its anti-inflammatory efficacy on the skin. To that end, an NE vehicle developed for skin delivery was optimized and characterized. The resulting PGZ-NE showed good anti-inflammatory efficacy by decreasing the expression of inflammatory cytokines IL-6, IL-1β and TNF-α. The properties of the developed nanocarrier allowed achievement of a high permeation flux of PGZ through the skin as well as a high retained amount in the skin, likely due to the depot effect of ingredients, which assured a prolonged local action, with good skin tolerability among participating individuals. Consequently, these results suggest that PGZ-NE may be used as an alternative treatment for inflammatory skin diseases such as rosacea, atopic dermatitis or psoriasis.

We also recommend Trading Suppliers and Manufacturers of Pioglitazone (cas 111025-46-8). Pls Click Website Link as below: cas 111025-46-8 suppliers

Prev:Research paperDouble-blind, placebo-controlled trial of Pioglitazone (cas 111025-46-8) for bipolar depression
Next:Original articlePPAR-γ agonist Pioglitazone (cas 111025-46-8) reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson’s disease)